Related Experiment Videos
Acute leukaemia during tamoxifen therapy
S Yalçin1, I Güllü, H Demiroğlu
1Hacettepe University Institute of Oncology, Ankara, Turkey.
Medical Oncology (Northwood, London, England)
|March 1, 1997
Summary
Tamoxifen therapy for breast cancer may increase the risk of secondary cancers, including acute myeloid leukemia (AML). This study reports two AML cases that developed during tamoxifen treatment.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Tamoxifen is a standard adjuvant therapy for breast cancer, improving survival and reducing recurrence.
- While generally well-tolerated, tamoxifen use has been linked to an increased incidence of secondary malignancies.
- Tamoxifen's potential carcinogenicity is attributed to genotoxic and epigenetic mechanisms involving reactive metabolites formed by cytochrome P450 enzymes.
Observation:
- Two cases of breast cancer patients developing acute myeloid leukemia (AML) during tamoxifen therapy are presented.
- These cases highlight a potential adverse effect of tamoxifen treatment.
Findings:
- Tamoxifen metabolites can form DNA adducts, suggesting a direct genotoxic pathway for carcinogenesis.
- The development of AML during tamoxifen therapy supports the hypothesis of tamoxifen-induced secondary cancers.
Implications:
- Clinicians should be aware of the potential risk of secondary AML in patients undergoing long-term tamoxifen treatment.
- Further research is warranted to elucidate the precise mechanisms and quantify the risk of tamoxifen-associated secondary malignancies.
- Monitoring for hematological malignancies may be considered in patients receiving tamoxifen therapy.